Lakefront Biotherapeutics NV LKFT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 102.04% | 110.50% | 3,275.15% | -1,341.01% | -1,341.01% |
| Total Depreciation and Amortization | -91.47% | -- | 4.87% | 112.11% | 112.11% |
| Total Amortization of Deferred Charges | -- | -- | -30.17% | -- | -- |
| Total Other Non-Cash Items | -270.91% | -286.98% | 80.68% | 219.08% | 219.08% |
| Change in Net Operating Assets | 88.20% | -83.13% | -1,295.95% | 18.51% | 18.51% |
| Cash from Operations | 67.88% | -138.31% | 12.70% | -72.66% | -72.66% |
| Capital Expenditure | 99.29% | 97.32% | 67.68% | -31.96% | -31.96% |
| Sale of Property, Plant, and Equipment | -- | -- | 13,940.63% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 108.17% | -91.84% | 40.59% | -504.66% | -504.66% |
| Other Investing Activities | 743.86% | 11.27% | 8.76% | 45.56% | 45.56% |
| Cash from Investing | 39.12% | -19.32% | 16.02% | 19.33% | 19.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -78.00% | 49.55% | 74.75% | 43.61% | 43.61% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -572.57% | 43.91% | 72.42% | 40.53% | 40.53% |
| Foreign Exchange rate Adjustments | 442.34% | 159.91% | -210.68% | -513.13% | -513.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 294.69% | -153.43% | 193.31% | -3,576.17% | -3,576.17% |